Verastem, Inc. - Common Stock (VSTM)

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Verastem's Q3 2025 results show a strong revenue beat from its new cancer drug launch, while its net loss widened. The stock dipped slightly on the mixed earnings news.

After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

In a study conducted in China, GFH375, also known as VS-7375 in the U.S., showed an overall response rate of 52% in patients with pancreatic ductal adenocarcinoma and 42% in those with non-small cell lung cancer.

Verastem's GFH375 trial data at ASCO 2025 shows a 52% response rate in pancreatic cancer and no dose-limiting toxicities across tested doses.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million funding for future developments.

The combination of Avutometinib capsules and Defactinib tablets, under the brand name Avmapki Fakzynja Co-pack, can now be used to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior treatment.

Verastem seeks FDA approval for avutometinib in recurrent LGSOC based on trial results, with a decision expected by June 2025.

VSTM stock results show that Verastem beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.